NVS — Novartis AG

Novartis Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Sales Growth: Net sales increased by 7% year-over-year, with core operating income also up 7%. Core margin stood at 39.3%.
• Core EPS: Reported at $2.25, reflecting a 10% increase.
• Free Cash Flow: Totaled $6.2 billion for the quarter, with $16 billion generated in the first nine months, up 26% year-over-year.
• U.S. Performance: Negative gross-to-net adjustments impacted results, particularly due to Medicare Part D redesign, but underlying growth would have been 9% for sales and 11% for core operating income without these adjustments.

2. Strategic Updates and Business Highlights

• Pipeline Progress: Key approvals included Rhapsido (FDA approval for CSU) and positive Phase III results for Ianalumab and Pluvicto.
• Priority Brands Performance:
  • Kisqali: Grew 68%, leading in both metastatic and early breast cancer markets.
  • Kesimpta: Increased by 44%, with strong demand in the U.S. and leading market share in several regions.
  • Pluvicto: Gained 45% growth, driven by new patient starts in the pre-taxane setting.
  • Leqvio: Up 54%, on track for over $1 billion in sales.
  • Scemblix: Grew 95%, nearing leadership in NBRx in the U.S.
• Cosentyx: Mixed results with a slight decline in sales due to a one-time adjustment but expected mid-single-digit growth for the full year.

3. Forward Guidance and Outlook

• 2025 Guidance: Reaffirmed with expectations of high single-digit growth in net sales and low teens growth in core operating income.
• 2026 Expectations: Anticipated to be a year of two halves, with initial pressures from generic erosion (notably Entresto) but expected recovery in the second half.
• Long-term Growth: Proposed acquisition of Avidity expected to enhance growth rates from 5% to 6% from 2024 to 2029.

4. Bad News, Challenges, or Points of Concern

• Generic Erosion: Significant headwinds anticipated from the entry of generics for Entresto, Tasigna, and Promacta, impacting overall margins.
• Cosentyx Performance: Despite stabilization, growth was affected by competitive pressures and a one-time adjustment, raising concerns about future market dynamics.
• Market Growth: Slower than expected growth in the HS market for Cosentyx, necessitating efforts to expand the patient base.
• Pipeline Risks: Competitive pressures from other therapies in the pipeline, particularly in the anti-APRIL space, could impact market share.

5. Notable Q&A Insights

• Policy Discussions: Ongoing discussions with the administration regarding pricing and reimbursement strategies, with an emphasis on addressing underlying industry issues.
• CapEx and R&D: Majority of the $23 billion commitment over five years is for R&D, with no significant increase in CapEx expected.
• Ianalumab Data: Concerns about secondary endpoints in trials, with a focus on patient-centric outcomes rather than just statistical significance.
• Kisqali and Kesimpta: No significant impact from competitor launches noted, with strong underlying operational growth reported.
• Pluvicto Launch: Positioned for strong growth with a well-established infrastructure, despite anticipated seasonal slowdowns.

Overall, Novartis demonstrated solid performance in Q3 2025, with strong sales from key brands and pipeline advancements, while navigating challenges from generic competition and market dynamics. The company remains optimistic about future growth, particularly with strategic acquisitions and ongoing product launches.